Asco 2023 story roundup
Evaluate Vantage and Scrip have been reporting from the Asco 2023 meeting and have covered the following stories:
8 June:
Asco 2023 movers – maintaining the momentum
7 June:
Novocure sinks as Lunar’s limitations become clear
6 June:
Dizal heralds a “super-Tagrisso”
Early first-line lung cancer data mined for datopotamab gold
5 June:
Enhertu hits with pan approach
Bicara eyes head and neck niche
Regeneron nips at Bristol’s heels in Lag3
Adaura survival boost for AZ’s Tagrisso (Scrip)
4 June:
Roche sees Morpheus and takes the red pill
Liver tox casts a pall over Servier’s Indigo readout
Trop2 could validate Merck’s savvy deal with Kelun
Deep and early responses lift hopes at Effector
Immunogen’s Elahere data in avastin-naïve ovarian cancer prompt discussion about earlier use (Scrip)
3 June:
Pfizer pushes forward in drug-resistant breast cancer
Six months on Gilead/Arcus’s Tigit deflates
Elevation follows in Astellas’s slipstream
A role for immuno-oncology in ovarian cancer at last
Jazz hits high note with updated zanidatamab data in biliary tract cancer (Scrip)
2 June:
Novartis’s adjuvant breast cancer win comes with caveats
Commands leaves the door open for Geron
30 May:
The article on Servier’s Indigo trial was jointly authored by Scrip's Alex Shimmings. Scrip and Evaluate Vantage are part of the same parent company, Norstella.
In addition, Jacob Plieth spoke with Brad Loncar on BiotechTV to preview the conference:
